Epidemiological, demographic, social, clinical features of manifestations of system red lupus in patients in Kazakhstan

Objective: to study and analyze the dynamics of prevalence, demographic, social, and clinical manifestations of systemic lupus erythematosus (SLE) in patients living in Kazakhstan.

Materials and methods. Official materials of the Ministry of Health of the Republic of Kazakhstan (2009–2018): statistical compendiums, a consolidated reporting form for medical treatment (N 12). 102 patients (100 women and 2 men) were included in the register of SLE with reliable SLE according to SLICC (ACR, 2012). Assessment of the debut of the disease was carried out according to archival material (medical history, outpatient records) of patients. The activity of the process was evaluated according to SLEDAI-2K, organ damage according to SLICC/ACR (2000).

Results. The total number of patients with SLE over 10 years (2009–2018) more than doubled, the growth rate was 101%. The overwhelming majority of patients with SLE are women (91%). In the study group, Asians (83.33%) predominated by race, of which Kazakhs (76.47%) were young (mean age – 33.85±10.58 years), with a disease duration of 5 (2; 9) years, time from the appearance of the first signs to verification of SLE – 4.5 (3; 12) years. The prevailing acute (49.0%), subacute (33.3%), rather than chronic (18.7%) variants of the course, with high activity according to SLEDAI-2K – 17.64±8.80. The most common clinical manifestations of the disease: skin lesions (98%), joints (79.4%), nervous system (49%), hematological (54.9%) and immunological (100%) disorders. The absence of organ damage (0 points) was detected in 10 (9.8%) cases, low (1 point) – in 21 (20.6%), medium (2–4) – in 61 (59.8%), high (over 4) – in 10 (9.8%) patients.

Conclusion. SLE remains a socially significant disease in Kazakhstan, as evidenced by the dynamics of the increase in incidence (101%) over 10 years (2009–2018). The prevalence of SLE is 24.7 per 100 thousand of the country’s population, lower than in other countries with a predominant Asian population or in comparison with Asian populations. A cohort of patients with SLE was represented by people of the Asian race (83.33%), Kazakhs (76.47%), and young people (33.85±10.58). The analysis revealed a delayed verification of the diagnosis of SLE (on average 4.5 (3; 12) years). Acute variants of the course of the disease with high disease activity according to SLEDAI-2K prevail. Common clinical manifestations of SLE are skin lesions, both acute and chronic (98%), joints (79.4%), damage to the nervous system (49%), hematological (54.9%) and immunological disorders (100%).

1. Rheumatology: Russian Clinical Guidelines. Edited by Nasonov EL. Moscow: GEOTAR-Media; 2019: 113−136 (In Russ.)

2. Issayeva BG, Saparbayeva MM, Khabizhanova VB, Gabdulina GKh, Isayeva SM, Kayirgali SM, et al. Systemic lupus erythematosus incidence rates in Kazakhstan and patient registry issues. Medisina (Almaty) = Medisine (Almaty). 2018;197(11):5−10 (In Russ.). doi: 10.31082/1728-452X-2018-197-11-5-10

3. Pyle K, Kennedy L. Diagnosis and treatment in rheumatology. The problematic approach; transl. NA Shostak. Moscow: GEOTAR-Media; 2011:143−160 (In Russ.).

4. Bengtsson AA, Rönnblom L. Systemic lupus erythematosus: Still a challenge for physicians. Intern Med. 2017;81(1):52−64. doi: 10.1111/Joim.12529.Epub 2016 Jun 16

5. Centers for Disease Control and Prevention (CDC). Trends in deaths from systemic lupus erythematosus – United States, 1979–1998. MMWR Morb Mortal Wkly Rep. 2002;51(17):371−374.

6. Bernatsky S, Clarke A, Gladman DD, Urowitz M, Fortin PR, Barr SG, et al. Mortality related to cerebrovascular disease in systemic lupus erythematosus. Lupus. 2006;15(12):835−839. doi: 10.1177/0961203306073133

7. Aseeva EA, Solovyev SK, Klyukvina NG, Popkova TV, Koylubayeva GM, Reshetnyak TM, et al. Irreversible organ damages in a cohort of patients with systemic lupus erythematosus (RENAISSANCE). Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice. 2016;54(4):404−411 (In Russ.). doi: org/10.14412/1995-4484-2016-404-411

8. Centers for Disease Control and Prevention, National Center for Health Statistics. Compressed Mortality File 1999–2016 on CDC WONDER Online Database. URL: http://wonder.cdc.gov/cmf-icd10.html (Accessed: June 1, 2018).

9. Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: Prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken). 2012;64(2):159−168. doi: 10.1002/acr.20683

10. Ocampo-Piraquive V, Nieto-Aristizábal I, Cañas CA, Tobón GJ. Mortality in systemic lupus erythematosus: causes, predictors and interventions. Expert Rev clin Immunol. 2018;14(12):1043−1053. doi: 10.1080/1744666X.2018.1538789

11. Yen EY, Shaheen M, Woo JMP, Mercer N, Li N, McCurdy DK, et al. 46-year trends in systemic lupus erythematosus mortality in the United States, 1968 to 2013: A nationwide population-based study. Ann Intern Med. 2017;167(11):777−785. doi: 10.7326/M17-0102

12. Watson P, Brennan A, Birch H, Fang H, Petri M. An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: Analysis and simulation of the Hopkins lupus cohort. Rheumatology (Oxford). 2015;54(4):623−632. doi: 10.1093/rheumatology/keu375

13. Jonson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum. 1995;38(4):551−558.

14. Osio-Salido E, Manapat-Reyes H. Epidemiology of systemic lupus erythematosus in Asia. Lupus. 2010;19(12):1365−1373. doi: 10.1177/0961203310374305

15. Albrecht K, Huscher D, Richter J, Backhaus M, Bischoff S, Kötter I, et al. Changes in referral, treatment and outcomes in patients with systemic lupus erythematosus in Germany in the 1990s and the 2000s. Lupus Sci Med. 2014;1:e000059. doi: 10.1136/lupus-2014-000059

16. Yee CS, Su L, Toescu V, Hickman R, Situnayake D, Bowman S, et al. Birmingham SLE cohort: Outcomes of a large inception cohort followed for up to 21 years. Rheumatology (Oxford). 2015;54(5):836−843. doi: 10.1093/rheumatology/keu412

17. Lerang K, Gilboe IM, Steinar Thelle D, Gran JT. Mortality and years of potential life loss in systemic lupus erythematosus: A population-based cohort study. Lupus. 2014;23(14):1546−1552. doi: 10.1177/0961203314551083

18. Fernández-Nebro A, Rúa-Figueroa Í, López-Longo FJ, Galindo-Izquierdo M, Calvo-Alén J, Olivé-Marqués A, et al. Cardiovascular events in systemic lupus erythematosus. A nation-wide study in Spain from the RELESSER Registry. Medicine (Baltimore). 2015;94(29):e1183. doi: 10.1097/MD.0000000000001183

19. Akbarian M, Faezi ST, Gharibdoost F, Shahram F. Systemic lupus erythematosus in Iran: A study of 2280 patients over 33 years. Int J Rheum Dis. 2010;13(4):374−379.

20. Rúa-Figueroa I, Richi, López-Longo FJ, Galindo M, Calvo-Alén J, Olivé-Marqués A, et al. Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) with emphasis on complete versus incomplete lupus differences. Medicine (Baltimore). 2015;94(1):e267. doi: 10.1097/MD.0000000000000267

21. van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K, et al. Treat-to-target in systemic lupus erythematosus: Recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-967. doi: 10.1136/annrheumdis-2013-205139

22. Soloviev SK, Aseeva EA, Popkova TV, Klyukvina NG, Reshetnyak TM, Lisitsina TA, et al. Treat-to-target SLE recommendations from the international task force and Russian experts’ commentaries. Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice. 2015;53(1):9−16 (In Russ.). doi: 10.14412/1995-4484-2015-9-16

23. Shamliyan TA, Dospinescu P. Additional improvements in clinical response from adjuvant biologic response modifiers in adults with moderate to severe systemic lupus erythematosus despite immunosuppressive agents: A systematic review and meta-analysis. Clin Ther. 2017; 39(7):1479-1506.e45. doi: 10.1016/j.clinthera.2017.05.359

24. Guerreiro CS, Isenberg DA. Belimumab in systemic lupus erythematosus (SLE): Evidence-to-date and clinical usefulness. Ther Adv Musculoskelet Dis. 2017;9(3):75−5. doi: 10.1177/1759720X17690474

25. Aseeva EA, Soloviev SK, Mesnyankina AA, Reshetnyak TM, Lopatina NE, Glukhova SI, et al. Results of an observational prospective study of the efficacy and safety of belimumab (Benlysta®) in systemic lupus erythematosus in real clinical practice. Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice. 2016;54(1):31−37. (In Russ). doi: 10.14412/1995-4484-2016-31-37

26. Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010;69(7):1269−1274. doi: 10.1136/ard.2009.117200

27. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151−1159. doi: 10.1136/annrheumdis-2018-214819

28. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736−745. doi: 10.1136/anrheumdis-2019.215089

29. Aseeva EA, Dubikov AI, Levasheva LA, Koylubayeva GM, Dzhetibayeva MK, Eraliyeva VT, et al. The registry of systemic lupus erythematosus patients, a Eurasian cohort (RENAISSANCE). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(5):520−526. (In Russ). doi: 10.14412/1995-4484-2016-520-526

30. Здоровье населения Республики Казахстан и деятельность организаций здравоохранения в 2012 году. Стат. сб. Астана. 2013:27–85. [The health of the population of the Republic of Kazakhstan and the activities of health organizations in 2012. Statistical collection of Astana. 2013:27−85 (In Russ.)]. URL: http://www.mz.gov.kz/sites/default/files/pages/sbornik_za./

31. Medstat. Form 12. Report on the number of diseases registered in the service area of the medical organiza- tion and contingents of patients under medical supervision. 2012– 2018. (In Russ). URL: http://www.medinfo.kz

32. Petri M, Orbai A-M, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthr. Rheum. 2012;64(8):2677−2686. doi: 10.1002/art.34473

33. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288−291. 34. Gladman DD, Goldsmith CH, Urowitz MB, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison. J Rheumatol. 2000;27(2):373−376.

34. Koilubaeva GM, Aseeva EA, Solovyev SK, Karimova ER, Nikishina NYu, Dzhuzenova FS, et al. Data from a prospective study of the features of systemic lupus erythematosus in patients of Kyrgyzstan (Eurasian RENAISSANCE Register). Modern Rheumatology Journal. 2020;14(1):40−48 (In Russ.). doi: 10.14412/1996-7012-2020-1-40-48

35. Conti F, Ceccarelli F, Perricone C. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: Results from a monocentric cohort. Lupus. 2016;25(7):719−726. doi: 10.1177/0961203315627199